Dr. Reddy's Laboratories confirms full compliance in FY26 audit
Dr. Reddy's Laboratories Limited reported full compliance with SEBI regulations for FY26 following an audit by M/s. Makarand M. Joshi & Co. The report confirmed no deviations, fines, or regulatory actions against the company.

*this image is generated using AI for illustrative purposes only.
Dr. Reddy's Laboratories Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The annual secretarial audit, conducted by M/s. Makarand M. Joshi & Co., Practicing Company Secretaries, verified the company's adherence to the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956, and various associated regulations including the Listing Obligations and Disclosure Requirements Regulations, 2015.
The certification process examined the company's documents, records, filings with stock exchanges, and its website. The report confirms that the listed entity complied with all provisions of the reviewed regulations and circulars during the review period. There were no deviations reported, and no fines were imposed.
Compliance Status
The audit assessed the company's adherence to specific governance and operational standards. The following table summarizes the compliance status for key areas:
| Sr. No. | Particulars | Compliance Status |
|---|---|---|
| 1. | Compliance with Secretarial Standards issued by ICSI | Yes |
| 2. | Adoption and timely updation of policies under SEBI Regulations | Yes |
| 3. | Maintenance and disclosures on Website | Yes |
| 4. | Disqualification of Director under Section 164 of Companies Act, 2013 | Yes |
| 5. | Identification and disclosure of material subsidiary companies | Yes |
| 6. | Preservation of Documents as per SEBI Regulations | Yes |
| 7. | Performance Evaluation of Board and Committees | Yes |
| 8. | Related Party Transactions (RPT) prior approval | Yes |
| 9. | Disclosure of events or information under Regulation 30 | Yes |
| 10. | Prohibition of Insider Trading Regulations, 2015 | Yes |
Regulatory Actions and Observations
The report explicitly states that no actions were taken against the listed entity, its promoters, directors, or subsidiaries by SEBI or the Stock Exchanges during the review period. Additionally, there were no resignations of statutory auditors from the company or its material subsidiaries, and no additional non-compliances were observed.
The audit also noted that the company had complied with SEBI Circular no SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, regarding the disclosure of Employee Benefit Scheme documents. The report, signed by Partner Makarand M. Joshi, assumes the responsibility of management for the authenticity of documents and clarifies that the certification is neither an audit nor an expression of opinion on the financial records.
Historical Stock Returns for Dr Reddys Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.18% | -1.39% | -2.32% | +4.34% | +4.85% | +23.70% |
How will this clean compliance record influence investor confidence and stock performance in the upcoming fiscal year?
What new SEBI regulations or circulars expected in 2026 could pose compliance challenges for Dr. Reddy's?
Will the company leverage its strong governance framework to pursue aggressive expansion or M&A activities?


































